The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ISAMAR: Multicenter phase II single arm trial of isatuximab (ISA) with/without lenalidomide (LEN) in pts with high risk smoldering multiple myeloma (HRSMM).
 
Elisabet Esteve Manasanch
Honoraria - Adaptive Biotechnologies; Amgen; BMS; Genentech; GlaxoSmithKline; Legend Biotech; Millennium; Novartis; Pfizer; Sanofi; Takeda; TeloGenomics
Research Funding - GlaxoSmithKline; Quest Diagnostics; Sanofi
 
Neha Korde
Honoraria - Cancer Network; Clinical Care Options; Intellisphere; Onc Live; PER; Remedy Health
Consulting or Advisory Role - Janssen Oncology
Research Funding - Abbvie; Amgen; Epizyme; Janssen
 
Hans C. Lee
Consulting or Advisory Role - Allogene Therapeutics; Bristol Myers Squibb; Celgene; Genentech; GlaxoSmithKline; Karyopharm Therapeutics; Legend Biotech; Monte Rosa Therapeutics; Oncopeptides; Pfizer; Sanofi; Takeda
Research Funding - Amgen; Celgene; GlaxoSmithKline; Janssen; Regeneron; Takeda
 
Krina K. Patel
Consulting or Advisory Role - Arcellx; Bristol-Myers Squibb; Caribou Biosciences; Celgene; Cellectis; Janssen; Karyopharm Therapeutics; Merck; Pfizer; Takeda; Takeda
Research Funding - Abbvie/Genentech; Allogene Therapeutics; Celgene/Bristol-Myers Squibb; Cellectis; Janssen; Nektar; Poseida; Precision Biosciences; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Melody Becnel
Honoraria - Curio Science
 
David Berrios
No Relationships to Disclose
 
Sheeba K. Thomas
Consulting or Advisory Role - Cellectar
Research Funding - Acerta Pharma; Ascentage Pharma; Bristol-Myers Squibb; Cellectar; Genentech
 
Swaminathan Padmanabhan Iyer
Honoraria - Seagen
Consulting or Advisory Role - Legend Biotech; Seagen; Secura Bio; Yingli Pharma
Speakers' Bureau - Targeted Oncology
Research Funding - Affimed Therapeutics (Inst); crispr therapeutics (Inst); Innate Pharma; Legend Biotech ; Merck; Rhizen Pharmaceuticals (Inst); Seagen (Inst); Spectrum Pharmaceuticals (Inst); Trillium Therapeutics (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Takeda
 
Sham Mailankody
Honoraria - OncLive/MJH Life Sciences; Physicans' Education Resource; Plexus
Consulting or Advisory Role - Janssen Oncology; Legend Biotech; Optum; Optum
Research Funding - Alimera Sciences (Inst); Bristol-Myers Squibb (Inst); Fate Therapeutics; Fate Therapeutics; Janssen Oncology (Inst); Juno Therapeutics (Inst); Takeda (Inst)
 
Behrang Amini
No Relationships to Disclose
 
Pei Lin
Consulting or Advisory Role - Abbvie
Research Funding - Heidelberg Pharma
Travel, Accommodations, Expenses - Abbvie
 
Zuzana Berkova
No Relationships to Disclose
 
Donna M. Weber
No Relationships to Disclose
 
Lei Feng
No Relationships to Disclose
 
Sattva Swarup Neelapu
Stock and Other Ownership Interests - Longbow Immunotherapy
Honoraria - MJH Life Sciences; Peerview
Consulting or Advisory Role - Adicet Bio; Alimera Sciences; Astellas Pharma; Athenex; Bluebird Bio; Bristol-Myers Squibb; Caribou Biosciences; Chimagen Biosciences; Fosun Kite; Gilead Sciences; ImmunoACT; Incyte; Janssen medical Affairs; Kite, a Gilead company; Morphosys; Orna Therapeutics; Sana Biotechnology; Sellas Life Sciences; Takeda
Research Funding - Adicet Bio; Alimera Sciences; Bristol-Myers Squibb; Gilead Sciences; Kite, a Gilead company; Precision Biosciences
Patents, Royalties, Other Intellectual Property - Patents related to cellular therapy
 
Sundar Jagannath
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen; Karyopharm Therapeutics; Legend Biotech; Regeneron; Sanofi; Takeda
Travel, Accommodations, Expenses - Brystol-Myers Squibb; Janssen Biotech
 
Michelle Ann Theobald Hildebrandt
No Relationships to Disclose
 
Robert Z. Orlowski
Stock and Other Ownership Interests - Asylia Therapeutics, Inc.
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; AstraZeneca; BioTheryX; Bristol-Myers Squibb; GlaxoSmithKline; IASO Biotherapeutics; Janssen; Karyopharm Therapeutics; Kite, a Gilead company; Meridian Therapeutics; Monte Rosa Therapeutics; Neoleukin Therapeutics; Oncopeptides; Regeneron; Sanofi; Takeda
Research Funding - Asylia Therapeutics, Inc. (Inst); BioTheryX (Inst); CARsgen Therapeutics (Inst); Celgene/Bristol-Myers Squibb (Inst); Exelixis (Inst); Heidelberg Pharma (Inst); Janssen Biotech (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Asylia Therapeutics, Inc.
 
Ola Landgren
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Karyopharm Therapeutics; Medscape
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen
Research Funding - Amgen (Inst); Janssen (Inst); Pfizer (Inst)